News
AMD
FDA approves Izervay for treatment of geographic atrophy
The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
age related macular degeneration
AMD patients with visual disability at higher risk of cardiovascular disease
Researchers at Sungkyunkwan University School of Medicine in Korea conducted a nationwide cohort study involving nearly 4 million adults.
age-related macular degeneration
FDA approves first drug to treat geographic atrophy
Geographic atrophy typically affects people over the age of 50 and is one of the main causes of vision loss in the United States.
age-related macular degeneration
Potential cause of AMD identified
Researchers discovered a rare genetic variant that generates malformed proteins that change the stability of the membrane attack complex (MAC).
age-related macular degeneration
Higher serum vitamin D levels play a role in stages of AMD
Researchers recently examined data from the National Health and Nutrition Examination Survey (NHANES) to determine the link between serum vitamin D levels and the odds of developing different subt...
age-related macular degeneration
Macular degeneration linked to obesity
Researchers were examining why some people with a genetic predisposition develop age-related macular degeneration (AMD) while others with the genetic predisposition do not.
AMD
AI algorithm may be a helpful tool for determining progression of AMD
Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.
age-related macular degeneration
Lab-grown retinal cells indicate possibility of clinical trials
Researchers hope that these cells are ready to be studied in human clinical trials
age related macular degeneration
Genetic link between COVID risk and macular-degeneration
Researchers analyzed genetic data from more than 16,000 people with AMD, more than 50,000 people with COVID along with control groups.